Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

NCT: NCT05683691 · ACTIVE_NOT_RECRUITING

NCT IDNCT05683691
StatusACTIVE_NOT_RECRUITING
Start Date2023-05-16
SponsorFrancis Medical Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑